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INTRODUCTION
Liver transplantation is associated with marked
hemodynamic, hematologic, and metabolic abnor-
malities (1, 2). Because the liver plays a key role in
maintenance of blood glucose, one of the metabolic
disorders involves glucose metabolism, so that glu-
cose regulation becomes a matter of concern during
liver transplantation (3-6). Several recent clinical
studies have demonstrated the efficacy of strict glu-
cose control for reducing the mortality rate of post-
operative or emergency patients (7, 8). This led to
the notion that strict perioperative glycemic control
is essential for preventing perioperative inflamma-
tory response and improving patient outcome. Fur-
thermore, recent studies have shown that reducing
the variability of blood glucose concentration may
play an important role in glucose management (9).
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However, it has also been shown that intensive in-
sulin treatment is sometimes difficult to perform
when using sliding-scale manual insulin injection
because hypoglycemia occurs frequently in spite of
frequent blood glucose testing. It has therefore been
suggested that continuous blood glucose monitor-
ing would be beneficial for maintaining target blood
glucose levels.
A recent report advocated the usefulness of a
closed-loop system (artificial endocrine pancreas),
which provides continuous monitoring and strict
control of blood glucose. The STG-22 (Nikkiso,
Tokyo, Japan) is a novel artificial endocrine pancreas
with a closed-loop glycemic control system that pro-
vides continuous blood glucose monitoring by means
of a glucose sensor electrode and subsequent auto-
matic insulin and glucose infusion to maintain ap-
propriate blood glucose levels (10). Our group also
reported the usefulness of a closed-loop system pro-
viding continuous monitoring and strict control of
peri-operative blood glucose in patients during sur-
gery (11). An artificial endocrine pancreas may thus
be useful for such accurate and continuous blood
glucose monitoring and strict glycemic control dur-
ing liver transplantation.
The purpose of this study was to evaluate the use-
fulness of the STG-22 closed-loop system for the
continuous monitoring and control of intraoperative
blood glucose of patients undergoing living-donor
liver transplantation. Our final goal is the establish-
ment of a new superior perioperative blood glucose
control method using an artificial endocrine pan-
creas during liver transplantation.
PATIENTS AND METHODS
This investigation conformed to the principles out-
lined in the Declaration of Helsinki. The study pro-
tocol was approved by the Ethics Committee on Hu-
man Studies of Tokushima University Hospital, and
written informed consent was obtained from each
patient. Sixteen patients undergoing living-donor
liver transplantation were enrolled in this study.
Intraoperative Management
For this comparative utility assessment study, can-
nulae were inserted into a peripheral vein and a
radial artery in the operating theater. Standard
monitoring included pulse oximetry, lead II of the
electrocardiogram for heart rate and automated ST-
segment trend analysis, and end-tidal capnography.
General anesthesia was induced using intravenous
fentanyl and propofol. Neuromuscular blocking was
obtained by rocuronium. Following tracheal intuba-
tion, the lungs were mechanically ventilated with a
combination of oxygen and air and the tidal volume
was adjusted to produce normocapnia (end-tidal car-
bon dioxide between 30 and 40 mmHg). Anesthesia
was maintained with isoflurane and fentanyl. After
induction of general anesthesia and tracheal intuba-
tion, a pulmonary artery catheter and a central ve-
nous catheter were inserted through the right in-
ternal jugular vein.
Glucose levels were controlled with either a man-
ual injection of insulin based on a commonly used
sliding scale (manual insulin group, n=8) or a pro-
grammed infusion of insulin determined by the
control algorithm of the STG-22 (programmed in-
sulin group, n=8). Regular insulin human (Humulin
R ; Eli Lilly and Company, Indianapolis, USA) was
used for both groups. Rapidlab860 (Bayer Medical,
Tokyo, Japan) was used for conventional blood
glucose assessment. For the programmed insulin
group, a 20G intravenous catheter (Insyte ; Becton
Dickinson Infusion Therapy Systems, Sandy, UT)
was inserted after anesthesia induction into a periph-
eral forearm vein and connected to the STG-22 for
continuous blood glucose monitoring. The target
glucose level of 80-150 mg/dwas attained for both
groups as determined with a radial arterial catheter
used for intermittent blood glucose sampling. Sam-
ples were obtained during surgery after an estab-
lished protocol of discarding 2 ml of blood before
withdrawal of the actual blood sample by the same
anesthesiologist.
Equipment
The STG-22 provides continuous blood glucose
monitoring through a dual lumen catheter blood
sampling technique, a high-quality roller pump
(multichannel pump) and a glucose sensor electrode
with a glucose oxidase membrane. Before starting
blood glucose monitoring, a two-point calibration
was performed using a standard solution for internal
calibration (glucose concentration : 0 mg/d) and
a standard glucose solution (200 mg/d). During
blood glucose monitoring, internal calibration using
the standard solution for internal calibration was per-
formed automatically every 4 h. After calibration of
the equipment, blood was sampled continuously
from the peripheral vein at a rate of 2 ml/h and con-
tinuously diluted with a heparinized isotonic solu-
tion. The diluted blood was further diluted with an
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isotonic buffer solution of phosphoric acid, pH 7.4,
after which the glucose sensor electrode was ex-
posed to the sampled blood. The multichannel pump
and the glucose sensor electrode both had an accu-
racy of5%. The accuracy and reliability of this sys-
tem during and after surgery have been confirmed
(12, 13).
Data collection
The resultant 78 scores for paired blood glucose
levels obtained with continuous glucose measure-
ments (STG-22) and with conventional intermittent
glucose measurements (Rapidlab 860) were com-
pared. For each patient, the mean and standard de-
viation (SD) of blood glucose concentration during
surgery (Glu-Ave and Glu-SD) were calculated as
the arithmetical mean and SD of the entire set of
measurements. To evaluate relative variability, the
coefficient of variability (Glu-CV=Glu-SD100 /
Glu-Ave) (9) was also calculated and the maximum
blood glucose level of each patient (Glu-Max) was
adopted as the highest value occurring during sur-
gery.
Statistical analysis
The accuracy of continuous glucose measure-
ments (STG-22) and of conventional intermittent
glucose measurements (Rapidlab 860) during liver
transplantation was compared by means of the
Bland-Altman plot (14). In addition, the values ob-
tained with the two methods were subjected to cor-
relation analysis. Other data were analyzed with the
Mann-Whitney U-test or Fisher’s exact probability
test. Values are expressed as meanSD, and P
0.05 was considered to be statistically significant.
RESULTS
Figure 1 (left) shows a close correlation (r=0.88)
between continuous glucose measurements (STG-
22) and conventional intermittent glucose meas-
urements (Rapidlab 860) for the programmed in-
sulin group. Significant agreement was also ob-
served when the differences between the two meas-
urements were plotted against their mean value
(Figure 1, right).
Patient characteristics presented in Table 1 show
no significant differences between the two groups
for any of the values listed. Figure 2 shows a typi-
cal example of intraoperative blood glucose changes
in the manual insulin group. The blood glucose
concentration increased gradually during the pre-
anhepatic phase of transplantation, and significantly
so during reperfusion of the donor liver. Intraop-
erative blood glucose levels of the manual insulin
group fluctuated very widely (minimum : 85 mg/d,
maximum : 356 mg/d), so that strict control was
often difficult. On the other hand, stable blood glu-
cose values were maintained automatically (mini-
mum : 82 mg/d: maximum : 205 mg/d) for the
programmed insulin group. Figure 3 shows a typi-
cal example from the programmed insulin group.
Continuous monitoring and control of blood glucose
were successfully attained with the aid of the artifi-
cial endocrine pancreas. Before clamping of the he-
patic artery and portal vein, the blood glucose level
tended to decrease, but hypoglycemia was avoided
by means of appropriate glucose administration. The
blood glucose level suddenly started to increase af-
ter reperfusion of the portal vein and hepatic artery,
but only to a maximum of 150 mg/d, and the level
Figure 1. Accuracy of continuous blood glucose monitoring during liver transplantation
Left : Correlations between continuous glucose measurements (STG-22) and conventional intermittent glucose measurements (Rapidlab
860)
Right : Differences between the two measurements plotted against their mean (Bland-Altman plot of continuous glucose measurements
(STG-22) and conventional intermittent glucose measurements (Rapidlab 860))
The Journal of Medical Investigation Vol. 60 August 2013 207
Figure 2. Continuous blood glucose monitoring during liver transplantation (typical example from the manual insulin group)
Table 1 : Patient characteristics
Manual insulin group
(n=8)
Programmed insulin group
(n=8) P-value
Age (years) 56.03.7 48.612.4 NS
Height (cm) 158.08.5 159.48.9 NS
Weight (kg) 59.26.5 59.114.5 NS
Gender (male/female) 3/5 1/7 NS
Previous diabetes mellitus (Yes/No) 2/6 1/7 NS
Fasting blood glucose (mg/d) 104.121.4 91.410.9 NS
HbA1c (%) 5.52.1 4.20.7 NS
Underlying liver disease
Hepatitis B 5 3
Hepatitis C 3 3
Liver cirrhosis 7 6
Hepatocellular carcinoma 3 4
Estimated blood loss (m) 36173498 25513199 NS
Operation time (min) 780113 772118 NS
Anesthesia time (min) 918105 907122 NS
NS : not significant, MeanSD
Figure 3. Intensive insulin therapy during liver transplantation using the artificial endocrine pancreas (typical example from the pro-
grammed insulin group)
GIR : glucose infusion rate ; IIR : insulin infusion rate
During the preanhepatic phase, hypoglycemia was avoided by means of continuous glucose infusion, and after reperfusion, hyper-
glycemia was avoided by means of continuous insulin infusion.
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was controlled by means of appropriate insulin ad-
ministration.
Figure 4 shows the results of blood glucose man-
agement. Glu-Ave, Glu-SD, and Glu-Max for the
programmed insulin group (135.115.3, 27.3
7.7, 179.123.7 mg/d, respectively) were lower
than for the manual insulin group (188.133.2,
50.816.6, 272.864.4 mg/d), while Glu-CV for
the programmed insulin group was also lower than
that for the manual insulin group (20.14.9% vs.
26.96.1%). The overall success rate during sur-
gery, expressed as a percentage of all blood glucose
measurements within the target level range, was
77.520.6% for the programmed insulin group and
42.08.8% for the manual insulin group (P0.05)
(Figure 5, left). The total amount of insulin admin-
istered per patient during surgery was not signifi-
cantly different for the two groups (28.214.9 IU
vs. 20.220.8 IU) (Figure 5, right). No hypoglyce-
mia was detected in either group.
DISCUSSION
This is the first report of a closed-loop glucose-
sensing and insulin delivery system, in this case the
STG-22, being used for intraoperative management
during liver transplantation. Our results showed that
the programmed insulin group showed a higher suc-
cess rate for attaining the target blood glucose level
than the manual insulin group, even though the total
amount of insulin administered per patient during
surgery was not significantly different for the two
groups. No hypoglycemia was detected in either
group. In addition, stable blood glucose manage-
ment could be achieved with much less blood glu-
cose variability in the programmed than in the man-
ual insulin group.
During liver transplantation, blood glucose levels
change dramatically (3). As the liver plays an impor-
tant role in the maintenance of the plasma glucose,
liver transplantation causes disorders in glucose me-
tabolism. It is easy for hypoglycemia to occur when
insufficient glycogen is stored in the damaged liver
during the preanhepatic phase. In anticipation of
such a heightened tendency for hypoglycemia to oc-
cur, glucose consumption continues while the glu-
cose supply stops from the liver during the anhe-
patic phase. On the other hand, plasma glucose sud-
denly increases after reperfusion of the donor liver
as a result of release of the glucose load from the
donor liver or due to blood transfusion. Of special
note is that some studies have found that intraop-
erative hyperglycemia during liver transplantation-
ation was associated with an increased risk of post-
operative infection and mortality (5, 6). Hyperglyce-
mia is a direct cause of toxicity, and oxidative stress
in the cell due to high mitochondria peroxide pro-
duction may increase (15). The clinical importance
of hyperglycemia seems to be that morbidity and
Figure 5. Comparison of success rate and total amount of
insulin
NS : not significant. Values are expressed as meanSD.
(A)
(B)
Figure 4. Glucose management
A. Comparison of Glu-Ave and Glu-SD for the two groups
B. Comparison of Glu-Max and Glu-CV for the two groups
Glu-AVE : the mean of blood glucose concentration during sur-
gery ; Glu-SD : the standard deviation (SD) of blood glucose con-
centration during surgery ; Glu-Max : the maximum blood glu-
cose level in each patient ; Glu-CV : the coefficient of variability
(Glu-CV=Glu-SD100 /Glu-Ave)
# : Significant (P0.05) difference between groups. Values are
expressed as meanSD.
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mortality increase as was observed in a group of
critically ill patients. Because insulin performs a vital
function not only in blood glucose control, but also
as an anti-inflammatory and antioxidant agent, the
strict maintenance of normoglycemia by means of
intensive insulin treatment seems to reduce mortal-
ity as well as functional disorders of the liver kidney,
and the endothelium of the critically ill patient. (16).
Because insulin inhibits reactive oxygen species
production by controlling the proinflamatory effects
of NFκB, activator protein 1 (AP-1), early growth
response 1 (Egr-1) and high-mobility group box 1
(HMGB1) (16-18). Strict intraoperative glycemic
control, possibly using insulin infusions, may thus
improve outcomes following liver transplantation.
Intensive insulin therapy is used for critically ill
patients, and its specific aims are multiple organ pro-
tection and the prevention and treatment of infec-
tion by normalizing and maintaining blood glucose
levels normal levels (7, 8). Van den Berghe et al. (7)
were the first to report in 2001 that tight glycemic
control (maintaining blood glucose levels at 80-110
mg/d) improved morbidity and mortality in the sur-
gical intensive care unit (ICU). They demonstrated
that the overall ICU mortality rates dropped from 8%
to 4.6% and from 20.2% to 10.6% for patients requir-
ing more than 5 days of intensive care. Many modi-
fied versions of the original therapy have since been
introduced with the aim of attaining a blood glu-
cose level upper limit of around 140 to 180 mg/d
(19-21). The most notable reduction in mortality re-
sulting from this therapy involves death due to mul-
tiple-organ failure with a proven septic focus. Lower
blood glucose levels have been recommended in in-
ternational consensus guidelines as a means of im-
proving patient outcomes. The results of these trials
indicate that intraoperative blood glucose control
that maintains blood glucose levels 150 mg/d
should be considered of vital importance.
Some recent negative reports about intensive in-
sulin therapy have led to a reconsideration of such
therapy (22-24). The results of the NICE-SUGAR
study were presented in the March issue of the New
England Journal of Medicine in 2009 (22). Con-
trary to expectations, the mortality for the intensive
therapy group (target blood sugar value : 81-108
mg/d) after 90 days was higher (27.5% vs. 24.9%)
than that for the conventional therapy group (target
blood sugar value : 144-180 mg/d). Do these find-
ings mean that intensive insulin therapy should be
discarded entirely? Although this is probably not
the case, it is clear that there is an urgent need for
the establishment of a new blood glucose control
method that does not cause hypoglycemia. In addi-
tion, a recent study has shown that reducing variabil-
ity of blood glucose concentration may play an im-
portant role in glucose management (9).
In December 2007, our clinical team at Tokushima
University initiated a clinical trial to evaluate the ef-
ficacy of the artificial pancreas for strict periopera-
tive glycemic control of intra-operative patients. Two
STG-22 artificial pancreas systems were put into
clinical use at our institution for intra- and post-
operative glucose control (11). An artificial pan-
creas (STG-22) was developed by Nikkiso (Tokyo,
Japan), which collects venous blood continuously
for continuous blood glucose monitoring. Further-
more, this system carries out direct measurements
of blood glucose and can therefore detect and show
rapid changes in blood glucose levels. The reliability
and accuracy of continuous blood glucose moni-
toring with the STG-22 has been verified in several
studies, such as the ones by Yamashita and col-
leagues (12, 13). In our study, blood glucose meas-
ured continuously during liver transplantation with
the STG-22 correlated strongly with measurements
obtained intermittently with a conventional labora-
tory glucometer.
Previous studies reported that no surgical site in-
fection occurred after liver resection in a group
whose perioperative blood glucose was controlled
with an artificial pancreas (25, 26), indicating that
lack of perioperative blood glucose control is related
to the incidence of postoperative infectious compli-
cations and longer hospitalization. As already men-
tioned, the artificial pancreas is a safe and effective
device for strict perioperative glycemic control with-
out hypoglycemia for patients who undergo hepatic
resection for liver diseases. In addition, the frequent
blood sugar measurement contributes to a reduc-
tion in work load for the staff and the shorter hos-
pitalization to a reduction in incident, medical ex-
penses (27). The next-generation artificial endocrine
pancreas, equipped with a disposable and modular
tubing circuit with an auto-priming function, auto-
matic calibration with quick response in sensor set-
up and a compact structure, is also available (28).
However, establishment of a new perioperative blood
glucose control method using an artificial endocrine
pancreas to make effective use of this advanced
equipment is urgently needed.
In conclusion, strict perioperative glycemic con-
trol is effective for the protection of many organs
and a reduced incidence of infection so that it is
T. Okada, et al. Blood glucose and liver transplantation210
reasonable to conclude that it can lead to improved
prognosis for liver transplantation. However, such
control is difficult to implement due to the need
for intermittent blood glucose measurements and
the manual administration of insulin. The STG-22
closed-loop system (an artificial endocrine pan-
creas) is effective for maintaining strict blood glu-
cose control during living-donor liver transplanta-
tion with minimal variability in blood glucose con-
centration. However, our clinical study has certain
limitations : 1) the sample size was small ; 2) it was
not a randomized control study ; 3) no outcome
study was performed. Determination of the optimal
target blood glucose range during liver transplan-
tation and the long-term clinical implications of use
of the artificial pancreas for perioperative glycemic
control are important questions for further investi-
gations of larger study groups.
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